Immunovia AB (0G8X) Stock Statistics & Valuation Metrics

Immunovia AB has a market cap or net worth of kr101.30M. The enterprise value is kr99.54.

Immunovia AB has 672,666,900 shares outstanding. The number of shares has decreased by -2.65% in one year.

Immunovia AB’s return on equity (ROE) is -2.25 and return on invested capital (ROIC) is -108.35%.

The current PE Ratio of Immunovia AB is ―. Immunovia AB’s PEG ratio is 0.00986.

In the last 12 months, Immunovia AB had revenue of 685.00K and earned -145.91M in profits. Earnings per share was -0.42.

In the last 12 months, operating cash flow was -77.35M and capital expenditures -5.56M, giving a free cash flow of -82.91M billion.

Immunovia AB pays an annual dividend of ―, resulting in a dividend yield of ―

Immunovia AB upcoming earnings date is Nov 5, 2026, Before Open (Confirmed).

Immunovia AB as a current ratio of 5.12, with Debt / Equity ratio of 13.84%

In the past 12 months, Immunovia AB has paid 0.00 in taxes.

Immunovia AB EV to EBITDA ratio is -0.02, with an EV/FCF ratio of -0.02.

Immunovia AB has kr34.90M in cash and marketable securities with kr3.27M in debt, giving a net cash position of kr31.63M billion.

Gross margin is -1309.75%, with operating margin of -11606.42%, and net profit margin of -21301.46%.

The average price target for Immunovia AB is ―, which is 11.43% higher than the current price. The consensus rating is ―